News / Taiwan / economic_daily
Hanko Biotech Reports Successful Clinical Results for New Drug HCB101
Health Technology · Biotechnology · economic_daily · 2026-08-23
7827
Hanko Biotech's novel drug HCB101 has shown superior clinical efficacy in treating colorectal and gastric cancers, validating the company's FBDB drug platform.
What Happened
Clinical Breakthrough: Hanko Biotech announced that its novel drug, HCB101, has demonstrated promising results in early-stage clinical trials. The drug showed an objective response rate (ORR) superior to traditional therapies in treating second-line colorectal and gastric cancers.
Core Technology Platform: The company leverages its proprietary FBDB multi-functional biological drug platform to focus on myeloid cell-directed immunotherapy. This platform serves as the foundation for HCB101 and supports the company's broader drug development pipeline.
Validation of Immunotherapy: The successful clinical data provides human validation for macrophage-directed immunotherapy. This milestone confirms the clinical feasibility of the company's technology and establishes a solid foundation for future research and development.
Expansion Potential: Hanko plans to utilize the FBDB platform to expand its reach into a wider range of oncology and immune-related diseases. Recent disclosures at industry forums underscore the company's progress in the precision medicine market.